Stockreport

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data [Seeking Alpha]

Tango Therapeutics, Inc.  (TNGX) 
PDF Summary Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cance [Read more]